MichaelSHershfieldMD
Rheumatology • Durham, NCProfessor, Medicine, Duke University School of Medicine
Are you Dr. Hershfield?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 53 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4101 N Roxboro St
Durham, NC 27704Phone+1 919-684-8111
Summary
- Dr. Michael Hershfield, MD is a rheumatologist in Durham, North Carolina. He is currently licensed to practice medicine in North Carolina. He is affiliated with Durham Veterans Affairs Medical Center and is a Professor at Duke University School of Medicine.
Education & Training
University of California (San Diego) Medical CenterResidency, Internal Medicine, 1974 - 1975
Philadelphia General HospitalInternship, Transitional Year, 1967 - 1968
Perelman School of Medicine at the University of PennsylvaniaClass of 1967
Certifications & Licensure
NC State Medical License 1976 - 2023
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1980
Publications & Presentations
PubMed
- 1 citationsEvolving spectrum of adenosine deaminase (ADA) deficiency: Assessing genotype pathogenicity according to expressed ADA activity of 46 variants.Ines Santisteban, Francisco X Arredondo-Vega, Pawan Bali, Busra Dalgic, Hyun Ho Lee
The Journal of Allergy and Clinical Immunology. 2024-08-23 - Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.Elizabeth Daly Hicks, Geoffrey Hall, Michael S Hershfield, Teresa K Tarrant, Pawan Bali
Journal of Clinical Immunology. 2024-04-27 - 24 citationsOutcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC.Geoffrey D E Cuvelier, Brent R Logan, Susan E Prockop, Rebecca H Buckley, Caroline Y Kuo
Blood. 2022-08-18
Press Mentions
Fact-Checking, Pros and Cons of Cord Blood BankingJanuary 19th, 2021
ADA2 Deficiency: Case Series of Five Patients with Varying PhenotypesDecember 17th, 2019
Idiopathic, Refractory Sweet's Syndrome Associated with Common Variable Immunodeficiency: A Case Report and Literature ReviewMay 14th, 2019- Join now to see all
Grant Support
- Peg-Uricase As Therapy For Refractory GoutFood And Drug Administration2004–2006
- A Lymphoblast Model For Diseases Of Purine MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1986–2006
- Lymphoblast Model For Diseases Of Purine MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1994–2001
- Mammalian PEG Uricase For Therapy Of Intractable GoutNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1997
- Mammalian PEG Uricase For Therapy Of Intractable GoutNational Institute Of Diabetes And Digestive And Kidney Diseases1994
- A Lymphoblast Model For Diseases Of MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1991–1993
- Lymphoblast Model For Diseases Of MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1992
- Mechanism Of Immunopharmacologic Purine AnalogsNational Institute Of Allergy And Infectious Diseases1986–1990
- A Lymphoblast Model For Diseases Of Purine MetabolismNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985
Professional Memberships
- Member
- Master Member
